| Abstract | Anaerobic bacterium Clostridium botulinum produces seven different serotypes of botulinum neurotoxins (A-G), which specifically act at the peripheral cholinergic nerve terminals blocking the release of acethylcholine. Primary site of action of botulinum toxin type A (BT-A) is neuromuscular end plate where it specifically cleaves SNAP-25, one of the proteins necessary for neuroegzocytosis. The consequence is long-lasting muscle paralysis. Although BT-A is one of the most potent toxins in nature, over the last 20 years, intramuscular injections of nanogram quantities of BT-A have been used to treat various conditions characterized by increased muscle contraction, like dystonias, spasticity related to cerebral palsy etc but also for autonomic nervous system disorders, like hyperhydrosis. Long duration of action (several months) after peripheral application is the most prominent feature of the toxin's action. Although the acute mechanism of action on neuromuscular junction is largely investigated, there are still some unknowns related to: the passage of BT-A through epithelial barriers, specific recognition of peripheral cholinergic neurons. The mechanism of long duration of action, which is the base of therapeutic use of BT-A, is poorly understood. |
| Authors | Lidija Bach-Rojecky, Maja Relja, Boris Filipović, Zdravko Lacković
(Affiliation: Zavod za farmakologiju Farmaceutsko-biokemijskog fakulteta Sveucilista u Zagrebu.)
|
| Journal | Lijec̆nic̆ki vjesnik
(Lijec Vjesn)
Vol. 129
Issue 12
Pg. 407-14
(Dec 2007)
ISSN: 0024-3477 Croatia |
| Vernacular Title | Botulinum toksin tipa A i kolinergicni sustav. |
| PMID | 18383744
(Publication Type: English Abstract, Journal Article, Review)
|
| Chemical References |
- Botulinum Toxin Type A
- Neuromuscular Agents
|
| Topics |
- Animals
- Autonomic Nervous System
(drug effects)
- Botulinum Toxin Type A
(pharmacology, therapeutic use)
- Humans
- Neuromuscular Agents
(pharmacology, therapeutic use)
|
